Scarica l'app Stockscreener
0.8711
5.91%
-0.0547
Phio Pharmaceuticals Corp Borsa (PHIO) Ultime notizie
A cancer approach designed to help immune cells fight tumors is the focus of Phio's presentation. - Stock Titan
A director buys 10,000 shares of Phio Pharmaceuticals (PHIO) at $1.03 and $1.04 per share. - Stock Titan
Phio Pharmaceuticals CEO Robert J. Bitterman Awarded 400,000 Restricted Stock Units - Kalkine Media
Phio Pharmaceuticals Director Ronald Todd Plott Granted 17,000 Restricted Stock Units - Kalkine Media
Phio Pharmaceuticals CFO Lisa Cabott Carson Granted 108,000 Restricted Stock Units - Kalkine Media
A director’s grant at Phio Pharmaceuticals (PHIO) covers 17,000 shares that vest in a year. - Stock Titan
A CEO's stock award will vest after a year at Phio Pharmaceuticals (PHIO). - Stock Titan
After a stock award, Phio Pharmaceuticals (PHIO) CFO Lisa Cabott Carson reports holdings of 189,112 shares. - Stock Titan
Phio Pharmaceuticals Stockholders Endorse 2026 Annual Meeting Proposals Including Director Elections and Incentive Plan Expansion - Kalkine Media
Director Patricia Bradford Buys 6,500 Shares of Phio Pharmaceuti - GuruFocus
At $1.0127 a share, a Phio Pharmaceuticals (PHIO) director bought 6,500 shares. - Stock Titan
Phio Pharmaceuticals (PHIO) Chairman, President & CEO Robert Bit - GuruFocus
A CEO buys Phio Pharmaceuticals (PHIO) shares at $1.0289 each; reported direct holdings total 364,871 shares. - Stock Titan
Phio Pharmaceuticals Corp (NASDAQ: PHIO) Share Price, PHIO Stock News, PHIO Share Price & Updates - Kalkine
Phio Pharmaceuticals (NASDAQ: PHIO) Director Patricia A. Bradford Acquires 12,000 Shares at $1.03 Each - kalkinemedia.com
Phio Pharmaceuticals (PHIO) director buys shares with no 10b5-1 plan reported - Stock Titan
Phio Pharmaceuticals (PHIO) CEO has 68,550 shares withheld for taxes - Stock Titan
Phio Pharmaceuticals (PHIO) CFO’s 12,888-share tax move involves no market sale - Stock Titan
Form 8K Phio Pharmaceuticals Corp For: 14 September By Investing.com - Investing.com Canada
Form 8K Phio Pharmaceuticals Corp For: 14 September By Investing.com - Investing.com UK
Phio Pharmaceuticals to present clinical updates on cancer treatment PH-762 at H.C. Wainwright conference - Pluang
A potential nonsurgical treatment for skin cancers will be discussed at an investor conference - Stock Titan
Phio Pharmaceuticals Corp (PHIOW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Phio Pharmaceuticals director Plott buys $17,100 in shares - Investing.com
Phio Pharmaceuticals director Plott buys $17,100 in shares By Investing.com - Investing.com Canada
Phio Pharmaceuticals director Plott buys $17,100 in shares - Investing.com
Phio Pharmaceuticals (PHIO) director snaps up 15,000 shares - Stock Titan
Price to sales forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals (PHIO) Chairman Robert Bitterman Buys 10,00 - GuruFocus
Phio Pharmaceuticals (PHIO) CEO boosts holdings to 431,421 shares - Stock Titan
Price to earnings forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Price to earnings forward of Phio Pharmaceuticals Corp. – BOATS:PHIO - TradingView
Phio Pharmaceuticals Corp. SEC Filing (Aug 14, 2026) - Stock Titan
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Compound PH-894 Targeting BRD4 Protein - The National Law Review
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Compound PH-894 Targeting BRD4 Protein - EIN Presswire
Phio Pharmaceuticals Corp (NASDAQ: PHIO) Share Price, PHIO Stock News, PHIO Share Price & Updates - kalkine.ca
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 By Investing.com - Investing.com Canada
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 - Investing.com
Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894 - Bitget
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 - TMX Newsfile
Phio Pharmaceuticals Receives U.S. Notice of Allowance for PH-894 Patent Targeting BRD4 Protein via INTASYL® Platform - kalkine.ca
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 By Investing.com - Investing.com India
Enterprise value to revenue forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals Corp (PHIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Phio Pharmaceuticals Corp. Q2 2026: Net income $(4.14)M, EPS $(0.36) — 10-Q Summary - TradingView
Phio Pharmaceuticals posts $4.1M Q2 net loss, cash $13.0M; advances PH-762 program - TradingView
PHIO: PH-762 clinical progress accelerates as cash runway extends into 2027 amid rising R&D costs - TradingView
PHIO: Q2 2026 net loss widened to $4.1M as PH-762 advanced, with $13M in cash and ongoing funding needs - TradingView
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update - TMX Newsfile
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):